Skip to content

Nuvalent, Inc.

NUVL

CIK 0001861560 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
—
Q1 Mar 2026
Net Income (TTM)
−$415.95M
−63.1% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$5.66
−48.9% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
—
Q1 Mar 2026
Net Margin
—
Q1 Mar 2026
Free Cash Flow (TTM)
—
Q1 Mar 2026
Cash
$159.73M
Q1 Mar 2026
Total Debt
—
Q1 Mar 2026
Shares Outstanding
3.13M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings